Contribution of fluorescence in situ hybridization to immunohistochemistry for the evaluation of HER-2 in breast cancer

Anna M. Cianciulli, Claudio Botti, Angela M. Coletta, Simonetta Buglioni, Raffaella Marzano, Maria Benevolo, Antonio Cione, Marcella Mottolese

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

The main focus of the present study was to assess the efficacy of interphase cytogenetics using fluorescence in situ hybridization (FISH) as a valid alternative to immunohistochemistry (IHC) in paraffin-embedded tissue sections and/or the efficacy of the combination of the two methods, while, at the same time, aiming to provide additional information on the use of the two methods. For this study, selected breast cancer patients (n=66) were tested for HER-2 gene amplification by FISH. The probe contains DNA sequences specific for the HER-2 human gene locus and hybridizes to the 17q11.2∼q12 region of human chromosome 17. The same samples were tested previously for HER-2 overexpression by two monoclonal antibodies (300G9 and CB11), recognizing an extracellular and an internal domain of gp185Her-2, respectively. HER-2 overexpression also was evaluated using the HerceptTest Kit (Dako, Milan, Italy). The HerceptTest was performed according to the manufacturer's standard procedures, and results were scored on a 0 to 3+ scale. A total of 34 (51%) of 66 breast tumors enrolled in this study were positive by FISH. Of the 34 cases amplified by FISH, 9 were negative by IHC using both monoclonal antibody (MoAb) 300G9 and MoAb CB11, with a concordance rate from 80.3% to 83.3%. A higher concordance was verified (92.4%) when we used the HerceptTest Kit. Of the 32 cases found negative with the HerceptTest, FISH analysis identified HER-2 gene amplification in more than 10%. Our results indicate that with the combined use of both methods, several amplified samples classified negative by IHC can be used thus improving therapeutic planning for specific therapy with the monoclonal antibody trastuzumab.

Original languageEnglish
Pages (from-to)66-71
Number of pages6
JournalCancer Genetics and Cytogenetics
Volume133
Issue number1
DOIs
Publication statusPublished - 2002

Fingerprint

Fluorescence In Situ Hybridization
erbB-2 Genes
Immunohistochemistry
Breast Neoplasms
Monoclonal Antibodies
Gene Amplification
Chromosomes, Human, Pair 17
Interphase
Human Chromosomes
Cytogenetics
Paraffin
Italy
Therapeutics

ASJC Scopus subject areas

  • Cancer Research
  • Genetics
  • Molecular Biology

Cite this

Contribution of fluorescence in situ hybridization to immunohistochemistry for the evaluation of HER-2 in breast cancer. / Cianciulli, Anna M.; Botti, Claudio; Coletta, Angela M.; Buglioni, Simonetta; Marzano, Raffaella; Benevolo, Maria; Cione, Antonio; Mottolese, Marcella.

In: Cancer Genetics and Cytogenetics, Vol. 133, No. 1, 2002, p. 66-71.

Research output: Contribution to journalArticle

Cianciulli, Anna M. ; Botti, Claudio ; Coletta, Angela M. ; Buglioni, Simonetta ; Marzano, Raffaella ; Benevolo, Maria ; Cione, Antonio ; Mottolese, Marcella. / Contribution of fluorescence in situ hybridization to immunohistochemistry for the evaluation of HER-2 in breast cancer. In: Cancer Genetics and Cytogenetics. 2002 ; Vol. 133, No. 1. pp. 66-71.
@article{b1a9d6985b7f4443b87b9b9f3055b6d2,
title = "Contribution of fluorescence in situ hybridization to immunohistochemistry for the evaluation of HER-2 in breast cancer",
abstract = "The main focus of the present study was to assess the efficacy of interphase cytogenetics using fluorescence in situ hybridization (FISH) as a valid alternative to immunohistochemistry (IHC) in paraffin-embedded tissue sections and/or the efficacy of the combination of the two methods, while, at the same time, aiming to provide additional information on the use of the two methods. For this study, selected breast cancer patients (n=66) were tested for HER-2 gene amplification by FISH. The probe contains DNA sequences specific for the HER-2 human gene locus and hybridizes to the 17q11.2∼q12 region of human chromosome 17. The same samples were tested previously for HER-2 overexpression by two monoclonal antibodies (300G9 and CB11), recognizing an extracellular and an internal domain of gp185Her-2, respectively. HER-2 overexpression also was evaluated using the HerceptTest Kit (Dako, Milan, Italy). The HerceptTest was performed according to the manufacturer's standard procedures, and results were scored on a 0 to 3+ scale. A total of 34 (51{\%}) of 66 breast tumors enrolled in this study were positive by FISH. Of the 34 cases amplified by FISH, 9 were negative by IHC using both monoclonal antibody (MoAb) 300G9 and MoAb CB11, with a concordance rate from 80.3{\%} to 83.3{\%}. A higher concordance was verified (92.4{\%}) when we used the HerceptTest Kit. Of the 32 cases found negative with the HerceptTest, FISH analysis identified HER-2 gene amplification in more than 10{\%}. Our results indicate that with the combined use of both methods, several amplified samples classified negative by IHC can be used thus improving therapeutic planning for specific therapy with the monoclonal antibody trastuzumab.",
author = "Cianciulli, {Anna M.} and Claudio Botti and Coletta, {Angela M.} and Simonetta Buglioni and Raffaella Marzano and Maria Benevolo and Antonio Cione and Marcella Mottolese",
year = "2002",
doi = "10.1016/S0165-4608(01)00559-3",
language = "English",
volume = "133",
pages = "66--71",
journal = "Cancer Genetics and Cytogenetics",
issn = "0165-4608",
publisher = "Elsevier Inc.",
number = "1",

}

TY - JOUR

T1 - Contribution of fluorescence in situ hybridization to immunohistochemistry for the evaluation of HER-2 in breast cancer

AU - Cianciulli, Anna M.

AU - Botti, Claudio

AU - Coletta, Angela M.

AU - Buglioni, Simonetta

AU - Marzano, Raffaella

AU - Benevolo, Maria

AU - Cione, Antonio

AU - Mottolese, Marcella

PY - 2002

Y1 - 2002

N2 - The main focus of the present study was to assess the efficacy of interphase cytogenetics using fluorescence in situ hybridization (FISH) as a valid alternative to immunohistochemistry (IHC) in paraffin-embedded tissue sections and/or the efficacy of the combination of the two methods, while, at the same time, aiming to provide additional information on the use of the two methods. For this study, selected breast cancer patients (n=66) were tested for HER-2 gene amplification by FISH. The probe contains DNA sequences specific for the HER-2 human gene locus and hybridizes to the 17q11.2∼q12 region of human chromosome 17. The same samples were tested previously for HER-2 overexpression by two monoclonal antibodies (300G9 and CB11), recognizing an extracellular and an internal domain of gp185Her-2, respectively. HER-2 overexpression also was evaluated using the HerceptTest Kit (Dako, Milan, Italy). The HerceptTest was performed according to the manufacturer's standard procedures, and results were scored on a 0 to 3+ scale. A total of 34 (51%) of 66 breast tumors enrolled in this study were positive by FISH. Of the 34 cases amplified by FISH, 9 were negative by IHC using both monoclonal antibody (MoAb) 300G9 and MoAb CB11, with a concordance rate from 80.3% to 83.3%. A higher concordance was verified (92.4%) when we used the HerceptTest Kit. Of the 32 cases found negative with the HerceptTest, FISH analysis identified HER-2 gene amplification in more than 10%. Our results indicate that with the combined use of both methods, several amplified samples classified negative by IHC can be used thus improving therapeutic planning for specific therapy with the monoclonal antibody trastuzumab.

AB - The main focus of the present study was to assess the efficacy of interphase cytogenetics using fluorescence in situ hybridization (FISH) as a valid alternative to immunohistochemistry (IHC) in paraffin-embedded tissue sections and/or the efficacy of the combination of the two methods, while, at the same time, aiming to provide additional information on the use of the two methods. For this study, selected breast cancer patients (n=66) were tested for HER-2 gene amplification by FISH. The probe contains DNA sequences specific for the HER-2 human gene locus and hybridizes to the 17q11.2∼q12 region of human chromosome 17. The same samples were tested previously for HER-2 overexpression by two monoclonal antibodies (300G9 and CB11), recognizing an extracellular and an internal domain of gp185Her-2, respectively. HER-2 overexpression also was evaluated using the HerceptTest Kit (Dako, Milan, Italy). The HerceptTest was performed according to the manufacturer's standard procedures, and results were scored on a 0 to 3+ scale. A total of 34 (51%) of 66 breast tumors enrolled in this study were positive by FISH. Of the 34 cases amplified by FISH, 9 were negative by IHC using both monoclonal antibody (MoAb) 300G9 and MoAb CB11, with a concordance rate from 80.3% to 83.3%. A higher concordance was verified (92.4%) when we used the HerceptTest Kit. Of the 32 cases found negative with the HerceptTest, FISH analysis identified HER-2 gene amplification in more than 10%. Our results indicate that with the combined use of both methods, several amplified samples classified negative by IHC can be used thus improving therapeutic planning for specific therapy with the monoclonal antibody trastuzumab.

UR - http://www.scopus.com/inward/record.url?scp=0036121981&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036121981&partnerID=8YFLogxK

U2 - 10.1016/S0165-4608(01)00559-3

DO - 10.1016/S0165-4608(01)00559-3

M3 - Article

C2 - 11890992

AN - SCOPUS:0036121981

VL - 133

SP - 66

EP - 71

JO - Cancer Genetics and Cytogenetics

JF - Cancer Genetics and Cytogenetics

SN - 0165-4608

IS - 1

ER -